Get started
Author

Robert Hettle

Observed names: Hettle, Robert, R Hettle, R. Hettle
ORCID: 0000-0002-1100-1266
Observed ORCID: 0000-0002-1100-1266
OpenAlex ID: A5080315218
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2017 · Robert Hettle, Mark Corbett, et al. · Health Technology Assessment · 126
PDF
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
2019 · Mark Robson, Kathryn J. Ruddy, et al. · European Journal of Cancer · 86
Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis
2017 · Mohd Kashif Siddiqui, Inderpreet Singh Khurana, et al. · Current Medical Research and Opinion · 86
PDF
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
2021 · Michael Friedlander, Kathleen N Moore, et al. · The Lancet Oncology · 58
Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
2015 · Lara J. Wolfson, Anna Walker, et al. · PLoS ONE · 49
PDF
Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
2018 · Robert Hettle, Gerard Harty, et al. · Journal of Medical Economics · 43
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
2021 · Ignace Vergote, Isabelle Ray-Coquard, et al. · European Journal of Cancer · 30
Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review
2021 · Sukhvinder Johal, Robert Hettle, et al. · Journal of Thoracic Disease · 29
PDF
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
2017 · Daniel Wirth, Ramesh Dass, et al. · BMC Health Services Research · 25
PDF
Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium
2012 · Robert Hettle, Hanne Wouters, et al. · Respiratory Medicine · 25
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
2020 · Dominic Muston, Robert Hettle, et al. · Gynecologic Oncology · 21
Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial
2023 · Michael J. Sweeting, Mark J. Rutherford, et al. · Medical Decision Making · 20
PDF
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
2017 · Luigi R. Codecasa, Mondher Toumi, et al. · Journal of Market Access & Health Policy · 18
An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy
2011 · Koo Wilson, Robert Hettle, et al. · European Journal of Preventive Cardiology · 16
A matching‐adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia
2023 · Adam S. Kittai, Alan Skarbnik, et al. · American Journal of Hematology · 14
Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer
2021 · Charles McCrea, Robert Hettle, et al. · Journal of Comparative Effectiveness Research · 12
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
2021 · Robert Hettle, Charles McCrea, et al. · Therapeutic Advances in Medical Oncology · 12
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2021 · Rachel Evans, Neil Hawkins, et al. · Targeted Oncology · 11
PDF
Population adjusted indirect comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 studies of olaparib with or without bevacizumab, bev alone and placebo in the maintenance treatment of women with newly diagnosed stage III/IV ovarian cancer with BRCA mutation
2020 · I.B. Vergote, K.N. Moore, et al. · Gynecologic Oncology · 11
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy – General mapping algorithms
2015 · Robert Hettle, John Borrill, et al. · ClinicoEconomics and Outcomes Research · 11
PDF
Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer
2015 · Robert Hettle, John Posnett, et al. · Journal of Medical Economics · 11
PDF
Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer
2023 · Hedy L. Kindler, Hyun Kyoo Yoo, et al. · Cancer · 9
PDF
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients withBRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
2021 · David SP Tan, Jack Junjie Chan, et al. · Journal of Gynecologic Oncology · 9
Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.
2019 · Charles McCrea, Robert Hettle · Journal of Clinical Oncology · 9
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer
2018 · Rohit Mistry, Gaurav Suri, et al. · Current Medical Research and Opinion · 9
Works count: 111
Citation count: 861
H-index: 14
I10-index: 21
Year
Topic
Type